Michael Amoroso - 20 Jan 2026 Form 4 Insider Report for PRECISION BIOSCIENCES INC (DTIL)

Role
President and CEO, Director
Signature
/s/ Dario Scimeca, Attorney-in-Fact for Michael Amoroso
Issuer symbol
DTIL
Transactions as of
20 Jan 2026
Net transactions value
-$145,112
Form type
4
Filing time
22 Jan 2026, 18:49:01 UTC
Previous filing
04 Nov 2025
Next filing
27 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Amoroso Michael President and CEO, Director C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM /s/ Dario Scimeca, Attorney-in-Fact for Michael Amoroso 22 Jan 2026 0001830874

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DTIL Common Stock Options Exercise +8,888 +7.7% 124,463 20 Jan 2026 Direct F1, F2
transaction DTIL Common Stock Options Exercise +37,069 +30% 161,532 20 Jan 2026 Direct F1, F2
transaction DTIL Common Stock Options Exercise +69,421 +43% 230,953 20 Jan 2026 Direct F1, F2
transaction DTIL Common Stock Sale $145,112 -34,799 -15% $4.17 196,154 22 Jan 2026 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DTIL Restricted Stock Units Options Exercise $0 -8,888 -100% $0.000000 0 20 Jan 2026 Common Stock 8,888 Direct F2, F5
transaction DTIL Restricted Stock Units Options Exercise $0 -37,069 -50% $0.000000 37,069 20 Jan 2026 Common Stock 37,069 Direct F2, F6
transaction DTIL Restricted Stock Units Options Exercise $0 -69,421 -50% $0.000000 69,421 20 Jan 2026 Common Stock 69,421 Direct F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026.
F2 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3 The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.97 to $4.30. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
F5 On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
F6 On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
F7 On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.